2-Methylpyridine-5-boronic acid → (S)-2-(3-Hydroxypiperidin-1-yl)-6'-methyl-N-(4-(trifluoromethoxy)phenyl)-[3,3'-bipyridine]-5-carboxamide

Participants

Reaction Steps

The title compound was prepared in an analogous fashion to that described in Example 118 using (S)-5-bromo-6-(3-hydroxypiperidin-1-yl)-N-(4-(trifluoromethoxy)phenyl)nicotinamide (Stage 124.1) and (6-methylpyridin-3-yl)boronic acid to afford a white solid. UPLC-MS (condition 1) tR=2.16 min, m/z=473.1 [M+H]+, m/z=471.1 [M−H]−; 1H-NMR (400 MHz, DMSO-d6) δ ppm 1.19-1.39 (m, 2H) 1.53-1.62 (m, 1H) 1.78-1.86 (m, 1H) 2.55 (s, 3H) 2.55-2.62 (m, 1H) 2.69-2.78 (m, 1H) 3.42-3.51 (m, 2H) 3.55-3.63 (m, 1H) 4.37-5.01 (m, 1H) 7.36 (d, J=8.56 Hz, 2H) 7.42 (d, J=8.07 Hz, 1H) 7.83-7.89 (m, 2H) 7.93-8.00 (m, 1H) 8.07 (d, J=2.20 Hz, 1H) 8.71 (d, J=1.22 Hz, 1H) 8.75 (d, J=2.20 Hz, 1H) 10.29 (s, 1H).

Provenance & Evidence